Area of research
Oncology · Molecular Biology
Research interest
Research interests include Cancer Cells and Metastasis, Pancreatic and Hepatic Oncology Research, RNA modifications and cancer, and Ferroptosis and cancer prognosis.
Correction: MacCuaig et al. Toxicity Assessment of Mesoporous Silica Nanoparticles upon Intravenous Injection in Mice: Implications for Drug Delivery. <i>Pharmaceutics</i> 2022, <i>14</i>, 969.
A zinc transporter drives glioblastoma progression via extracellular vesicles-reprogrammed microglial plasticity
A zinc transporter drives glioblastoma progression via extracellular vesicles-reprogrammed microglial plasticity.
Evolving insights into pancreatic tumor initiation and progression through DCLK1-expressing tuft cells.
Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy.
Shared HLA-Bound Neoepitopes Are New Targets for Pancreatic Cancer Immunotherapy.
Corrigendum to "Targeting doublecortin-like kinase 1 reveals a novel strategy to circumvent chemoresistance and metastasis in ovarian cancer" [Cancer Lett. 2023 Dec 1;578:216437].
Glutaminase 2-Mediated Yes Associated Protein 1 Glutamylation Facilitates Immune Evasion in Pancreatic Ductal Adenocarcinoma.
Balancing Regeneration and Resistance: Targeting DCLK1 to Mitigate Gastrointestinal Radiation Injury and Oncogenesis.
Correction: Panneerselvam et al. Inflammatory Mediators and Gut Microbial Toxins Drive Colon Tumorigenesis by IL-23 Dependent Mechanism. <i>Cancers</i> 2021, <i>13</i>, 5159.
Supplementary Fig. S5 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
Figure 3 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
Supplementary Fig. S3 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
Supplementary Fig. S4 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
Figure 1 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
Supplementary Fig. S1 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
Data from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
Supplementary Table S1 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
Supplementary Fig. S2 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
Figure 4 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
Supplementary Fig. S6 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
Figure 2 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
The crosstalk between macrophages and cancer cells potentiates pancreatic cancer cachexia
The crosstalk between macrophages and cancer cells potentiates pancreatic cancer cachexia.
From Inflammation to Oncogenesis: Tracing Serum DCLK1 and miRNA Signatures in Chronic Liver Diseases.
Lysosomes Promote Cancer Metastasis via Exosome in PTEN-Deficient Tumors.
Epigenetic Landscape and Therapeutic Implication of Gene Isoforms of Doublecortin-Like Kinase 1 for Cancer Stem Cells.
Replication stress identifies novel molecular classification associated with treatment outcomes in pancreatic cancer.
Blocking of doublecortin-like kinase 1-regulated SARS-CoV-2 replication cycle restores cell signaling network.
Toxicity Assessment of Mesoporous Silica Nanoparticles upon Intravenous Injection in Mice: Implications for Drug Delivery